Vaccinia Capping Enzyme, GMP-Grade (GMP-VCS-VE101), DMF #038028
Catalog: GMP-VCS-VE101
Order now get it on
Product Description | The 7-methylguanosine cap structure (m7Gppp, Cap0) is a specific feature in eukaryotic mRNA, which is required for mRNA stability, splicing, nuclear export, effective translation, and mRNA decay. Vaccinia Capping Enzyme, a heterodimer of D1 and D12 subunits, adding the Cap0 structure to the 5' end of the RNA. The D1 subunit comprises an N-terminal RNA triphosphatase (TPase), a guanylyltransferase (GTase), and a C-terminal guanine-N7-methyltransferase (MTase). The D12 subunit binds and stimulates the MTase. NOTE: mRNA Cap 2'-O-Methyltransferase (Kactus #GMP-MEH-VE101) is required to generate Cap 1 structure that reduces cellular innate immune response when the RNA is used in vivo . This product has been filed with the FDA Drug Master Files (DMF) and is assigned DMF #038028. |
Application | RNA Modification Labeling 5' end of mRNA |
Concentration | 10U/µL |
Unit Definition | One unit is defined as the amount of enzyme required to incorporate 10 pmol of (α32P) GTP into an 80 nt transcript in 1 hour at 37°C. |
Source | Expressed in an E.coli strain carries the genes of the Vaccinia virus capping enzyme. |
Quality Standards | Activity (Capping modification and efficiency measurement): ≥ 10 kU/mL
Purity (SEC-HPLC): ≥ 95% Residual Endonuclease: Negative Residual Exonuclease: Negative Residual DNase: Negative Residual RNase: Negative Residual Protease: Negative Endotoxin: ≤ 10 EU/mL Residual Host Cell DNA: ≤ 100 pg/mg Residual Host Protein: ≤ 20 ng/mg Residual Heavy Metal: ≤ 10 ppm Bioburden: ≤ 1 CFU/10mL |
Form | Liquid |
Shipping | Shipped with blue ice |
Stability And Storage | -20±5°C for 24 months. Avoid repeated freeze-thaw cycles. |
You may also be interested in
View more associated products